Graves病患者血清细胞间粘附分子-1水平的观察

Soluble Intercellular Adhesion Molecule-1 in Serum of Patients with Graves Disease

目的 :探讨 Graves病 (GD)患者血清细胞间粘附分子 - 1(s ICAM- 1)的变化特点及其临床意义。方法 :采用超敏 EL ISA法检测 6 0例 GD初诊患者 (2 5例伴 Graves突眼 ,GO)、35例 GD缓解患者和 30名健康对照者血清 ICAM- 1水平。结果 :(1) GD初诊伴和不伴突眼者 s ICAM- 1浓度分别为 (331.15± 42 .2 3) pg/ ml和 (2 6 6 .13± 2 7.10 ) pg/ ml,GD缓解组 s ICAM- 1检测值为(179.94± 2 5 .0 4) pg/ m l,对照组为 (141.0 45± 2 .839) pg/ ml。 (2 ) GD初发 (伴或不伴突眼 )组 s ICAM- 1水平显著高于缓解组和对照组 ;GD缓解组 s ICAM- 1与正常对照比较差异无显著性 ;GD初发组的突眼患者 s ICAM- 1虽高于无突眼者 ,但二者比较无明显统计学差异。 (3) GD患者血清 s ICAM- 1与游离 T3(FT3)、游离 T4(FT4)及促甲状腺激素 (TSH)、甲状腺激素受体抗体(TRAb)水平明显正相关 ,但与 TSH浓度无显著相关关系。结论 :GD患者体内存在着 s ICAM- 1的明显异常 ,并且 s ICAM- 1水平与甲状腺功能状态和 (或 ) GD自身免疫状态密切相关。

Objective[WT5,5”BZ]:To evaluate the alteration and clinical significance of serum soluble intercellular adhesion molecule (sICAM 1) in patients with Graves disease (GD) with or without Graves ophthalmopathy (GO). Methods:The sixty patients (25/60 with GO) untreated GD patients, 35 treated GD patients with normal thyroid function and 30 healthy controls were investigated. sICAM 1 was measured by the method of ELISA. Results:The serum levels of sICAM 1 in untreated GD patients were (331.15±42.23) pg/ml (with GO) and (266.13±27.10) pg/ml (without GO), sICAM 1 in treated GD patients and normal control subjects were (179.94±25.04) pg/ml and (141.045±2.839) pg/ml respectively. The concentrations of sICAM 1 were significantly higher in untreated (with or without GO) group than that in the other two groups. No statistical difference was found in serum sICAM 1 levels between patients with and without GO, although the serum concentration of sICAM 1 was higher in GO patients. There was also no difference of sICAM 1 between treated GD patients and the controls. sICAM 1 levels were markedly correlated with the concentrations of FT3, FT4 and TSH receptor antibody (TRAb), but no correlation was found between sICAM 1 and TSH levels. Conclusions:Serum level of sICAM 1 is markedly elevated in untreated GD patients, especially in patients with GO. The determination of sICAM 1 is helpful for the identification of active ophthalmopathy and abnormal immunological manner of Graves disease. [WT5,5”HZ][